Leon-nanodrugs GmbH (LEON), a pharmatech firm specializing within the growth of nanoencapsulation methods for genetic materials and different lively substances, introduced in the present day the closing of a Sequence D financing spherical. New lead investor LBBW Enterprise Capital closed the spherical along with new traders and present shareholders like Albany Non-public Fairness Holdings Pty Ltd., CD-Enterprise GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Companions, TVM Life Science Innovation I L.P., and others.
“I’m more than happy that we’ve got accomplished this financing within the deliberate quantity. The brand new funds will likely be used to enhance the product portfolio. Our portfolio of main tools is designed to serve the Cell & Gene Remedy trade, enabling extremely financial GMP manufacturing of small and individualized batches of nanoencapsulated Cell & Gene Therapies. Along with the financing, this places us in place to pick out the very best strategic associate to convey these merchandise to the market”, commented Christian Nafe, Managing Director & CFO of LEON.
LEON’s strongly differentiated methods provide vital USP’s filling present trade gaps:
- NANOscreen: bench-top system for simplified formulation screening
- NANOlab®: bench-top system for quick and environment friendly course of growth
- NANOme® : aseptic manufacturing system for top throughput small- and individualized scale
- GMP manufacturing requiring no cleansing and sterilization resulting from a single use part
- NANOus® : giant scale manufacturing unit for industrial, sterile GMP batches.
The underlying FR-JET® reactor expertise is ready for future versatility of provider materials, and is optimized for minimal batch losses, and no scaling out. It’s included in all NANO-systems permitting to seamlessly scale up from course of growth to industrial manufacturing.
Dr. Frank Mühlenbeck, representing lead investor LBBW Enterprise Capital, will be part of LEON’s Supervisory Board. He acknowledged: “LEON’s merchandise permit the environment friendly growth and manufacturing of recent, upcoming modalities within the biopharma trade together with LNP’s with a particular give attention to decentralized patient-specific therapies. Along with this bench-to-bedside strategy, LEON’s merchandise additionally empower CDMOs providing centralized manufacturing of such therapies. We utterly perceive the trade want for next-generation manufacturing options and are glad to help LEON of their effort to advance their merchandise to commercialization.”
Dr. Hubert Birner, Managing Associate at TVM Life Science Administration and Chairman of LEON’s Supervisory Board acknowledged: “As a long-standing investor in LEON, we welcome the funding of LBBW VC, because it comes at a pivotal time for LEON to facilitate use of our lead merchandise out there. Whereas drugs of in the present day embraces an increasing number of Cell & Gene Therapies, a sensible answer for cost-efficient, quick and but dependable and protected manufacturing continues to be required.”